This study will help to better understand the course of disease in people with haemophilia (A or B \[with or without inhibitors\]) and the haemophilia care scenario in the selected countries and the experience so far in dealing with the condition. This is a survey-based study; hence no medications or other treatments will be provided to participants as a part of this study.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
For Experienced/Senior Treating Physicians
* Experienced/senior haematologist treating haemophilia (adult or paediatric) or physician treating patients with haemophilia. (PWH), with greater than 5 years of experience.
* Able to communicate in English or country specific language.
* Agree/sign informed consent before data collection. For Patients Organisations
* Patient organisation supporting haemophilia.
* Expert having greater than 3 years of work experience with the patient organisation.
* Expert level understanding of haemophilia landscape and care pathway in the relevant country.
* Able to communicate in English or country specific language.
* Agree/sign informed consent before data collection. For Patients/Caregivers
1. Patients of all age groups, diagnosed with haemophilia A or haemophilia B (with or without inhibitors) for greater than 2 years.
2. For patients less than 18 years of age (\*less than 19 years for South Korea), their caregivers aged greater than or equal to 18 years (\*greater than or equal to19 years for South Korea) should sign the informed consent.
\*For South Korea, the adult age is 19 years.
3. Able to communicate in English or country specific language.
4. Agree/sign informed consent before data collection.
Exclusion Criteria:
* There is no explicit exclusion criterion in this study, thus any participants group who answers "no" to any of the inclusion criteria will be excluded from the study.
Primary outcome measure(s)
Estimated prevalence of haemophilia — From start of data collection to end of data collection (approximately 5 months) Proportion \[%\] of individuals in a population
Estimated incidence of haemophilia — From start of data collection to end of data collection (approximately 5 months) Number of new cases of haemophilia
Estimated proportion of patients with haemophilia (PWH) who develop inhibitors (%) — From start of data collection to end of data collection (approximately 5 months) proportion \[%\] of individuals in a population
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.